## TER: Teradyne, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 1.61 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($181.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. TER vs. AMD: Which AI Component Supplier Stock Is the Better Buy?**
- Source: TradingView — Track All Markets | 20251222T170751 | Somewhat-Bullish | Relevance: 100%
- This article compares Teradyne (TER) and Advanced Micro Devices (AMD) as AI component suppliers, highlighting their market positions and growth potential. Teradyne is praised for its robust AI-driven semiconductor testing solutions and strong earnings surprises, while AMD is recognized for its expanding data center AI business despite facing intense competition. Ultimately, Teradyne is deemed the stronger pick with a Zacks Rank #2 (Buy) compared to AMD's Zacks Rank #3 (Hold).

**2. Exchange Traded Concepts LLC Has $26.89 Million Stock Holdings in Teradyne, Inc. $TER**
- Source: MarketBeat | 20251222T100953 | Somewhat-Bullish | Relevance: 100%
- Exchange Traded Concepts LLC reduced its stake in Teradyne, Inc. by 14.8% in Q3, now holding 195,330 shares valued at $26.89 million, despite other institutional investors increasing their positions. Analyst sentiment for Teradyne is a "Moderate Buy" with an average price target of $185.75, following recent target boosts from firms like UBS, Cantor Fitzgerald, and Citigroup. The company recently reported an earnings beat and trades near its 12-month high, but insiders have been net sellers.

**3. TER vs. AMD: Which AI Component Supplier Stock Is the Better Buy?**
- Source: The Globe and Mail | 20251222T180806 | Somewhat-Bullish | Relevance: 90%
- This article compares Teradyne (TER) and Advanced Micro Devices (AMD) as AI component suppliers, highlighting their growth prospects in the rapidly expanding semiconductor market. While AMD is a major player in high-performance CPUs and GPUs for AI, Teradyne specializes in critical automated test equipment and is integrating AI into its robotics. The analysis suggests Teradyne has higher growth potential due to stronger earnings surprises and a diversified AI-focused portfolio, despite AMD's expanding data center AI business facing stiff competition.

**4. Tubeless Insulin Pumps Market Size, Share, Trends | Top**
- Source: openPR.com | 20251222T101645 | Somewhat-Bullish | Relevance: 60%
- The tubeless insulin pumps market is projected to grow significantly from 2024 to 2031, driven by increasing demand for personalized and convenient diabetes management solutions. Recent innovations in the U.S. and Japan, including smaller form factors, longer wear times, and improved connectivity, are accelerating adoption. Key players like Insulet Corporation and F. Hoffmann-La Roche Ltd are major contributors to this market, which is segmented by type, component, application, and distribution channel, with North America holding the largest regional share.

**5. SYNOPSYS INC SEC 10-K Report**
- Source: TradingView — Track All Markets | 20251222T110811 | Neutral | Relevance: 56%
- Synopsys Inc. has released its fiscal year 2025 Form 10-K report, highlighting significant growth with total revenue of $7,054.2 million due to the Ansys Merger and organic growth. Despite an increase in gross margin, operating and net income decreased, impacted by higher expenses related to the Ansys acquisition. The company is focusing on debt reduction and leveraging its expanded product portfolio while navigating challenges like export controls and macroeconomic uncertainties.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Goldman Sachs | $230 | $148 | +55% |
| 2025-12-02 | Stifel | $225 | $162 | +39% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Goldman Sachs | up | Buy |
| 2025-12-02 | Stifel | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.00M) |
| Sells | 7 ($1.13M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (+2.1%)
- Blackrock Inc.: 8.4% (-7.2%)
- JPMORGAN CHASE & CO: 5.4% (+126.5%)
- State Street Corpora: 4.0% (+0.3%)
- Ameriprise Financial: 3.0% (+6.8%)

### Key Risks

1. High beta (1.85) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.61 elevated, pricing in significant growth expectations. Forward P/E 38.4x attractive for 46% earnings growth. Quality metrics strong (margin 16%). Balance sheet: low leverage (D/E 0.46). Revenue growth strong at 23% YoY. Analyst sentiment positive (2 raises, avg +47%). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $31.4B |
| Beta | 1.85 |
| 52W Range | $65.77 - $205.00 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.61 |
| Forward P/E | 38.4 |
| Current P/E | 56.0 |
| YoY Growth | 45.9% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -1.8% to 0.1% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.32), momentum weakening. RSI neutral at 60. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.11% (CS: 54) | Neutral |
| RSI_14 | 59.7 | Neutral |
| MACD Histogram | -1.32 | Bearish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.139x | Above |
| vs SMA200 | 1.703x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $197.22
- **Stop Loss:** $181.32 (8.1% risk)
- **Target:** $213.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 75
- **Position Value:** $14,791.50
- **Portfolio %:** 14.79%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-28 (Est: $1.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.79 | $0.85 | +7.4% |
| 2025Q2 | $0.54 | $0.57 | +4.9% |
| 2025Q1 | $0.62 | $0.75 | +21.7% |
| 2024Q4 | $0.91 | $0.95 | +4.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*